Prostate-specific membrane antigen (PSMA) ligands with improved tissue specificity

Novel PSMA ligands with reduced salivary and lacrimal gland uptake address side effect limitations of current compounds, enabling effective prostate cancer imaging and treatment with enhanced safety and dose flexibility.

JP7584426B2Active Publication Date: 2024-11-15UNIVERSITY OF HEIDELBERG +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021547181
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-14
Filing Date
2020-02-14
Publication Date
2024-11-15
Estimated Expiration
2040-02-14

AI Technical Summary

Technical Problem

Current PSMA ligands used for prostate cancer imaging and treatment exhibit high uptake by salivary and lacrimal glands, leading to significant side effects such as dry mouth symptoms, limiting therapeutic success and dose administration.

Method used

Development of novel radiopharmaceutical compounds with specific structures that reduce uptake by PSMA-expressing tissues, particularly prostate cancer cells, while minimizing side effects on salivary and lacrimal glands, utilizing a range of radionuclides for imaging and therapeutic applications.

Benefits of technology

The new compounds achieve reduced side effects on salivary and lacrimal glands, allowing for higher doses and wider therapeutic windows, maintaining effective imaging and treatment efficacy for prostate cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584426000072
    Figure 0007584426000072
  • Figure 0007584426000073
    Figure 0007584426000073
  • Figure 0007584426000074
    Figure 0007584426000074
Patent Text Reader

Abstract

The present invention relates to compounds of formula (1), as well as complexes comprising said compounds and radionuclides, and pharmaceutical compositions of each, which compounds have the following structure: 1 is H or -CH3, preferably H, and R 2 , R 3 and R 4 are each independently selected from the group consisting of -CO2H, -SO2H, -SO3H, -OSO3H, -PO2H, -PO3H and -OPO3H2; Q 1 is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl, and heteroaryl; Q 2is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl and alkylheteroaryl, and A is selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (=DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 1, 4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononanephosphinic acid (TRAP), 1,4,7-triazacyclononane Iononanephosphinic acid (TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO), 3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (=PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[ a chelator residue derived from a chelator selected from the group consisting of 5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A) p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA); 1 , X 2 , Y 1 , Y 2 , Z1 and Z 2 are each independently a charged amino acid, q is an integer from 0 to 3, n, m, and p are each independently an integer from 0 to 9, n1, n2, m1, m2, p1, and p2 are each independently an integer from 0 to 3, and n1+n2 > 0, m1+m2 > 0, and p1+p2 > 0, and n+m+p > 0. Furthermore, the present invention relates to compounds, complexes, and pharmaceutical compositions for use in treating, ameliorating, or preventing PSMA-expressing cancers, particularly prostate cancer and / or metastasis thereof. TIFF2022520799000069.tif34142
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates generally to the field of radiopharmaceuticals and their use as tracers, imaging agents in nuclear medicine and for the treatment of various disease states of PSMA-expressing cancers, particularly prostate cancer and its metastases. [Background technology]

[0002] Prostate cancer (PCa) is the leading cancer in the US and European population. It is estimated that at least 1-2 million men suffer from prostate cancer in the Western Hemisphere, and the disease affects one in six men between the ages of 55 and 85. There are more than 300,000 new cases of prostate cancer diagnosed each year in the USA. Mortality from the disease is second only to lung cancer. Currently, imaging methods with high resolution of the anatomy, such as computed tomography (CT), magnetic resonance (MR) imaging, and ultrasound, predominate over clinical imaging of prostate cancer. Currently, an estimated $2 billion is spent annually worldwide on surgical, radiation, drug therapy, and minimally invasive procedures. However, there is currently no effective treatment for recurrent, metastatic, androgen-independent prostate cancer.

[0003] Currently, a variety of experimental low molecular weight PCa imaging agents are radiolabeled choline analogues [ 18 F] Fluorodihydrotestosterone ([ 18 F]FDHT), anti-1-amino-3-[ 18 F] Fluorocyclobutyl-1-carboxylate (anti[ 18 F]F-FACBC, 11 C] acetate and 1-(2-deoxy-2-[ 18 F]fluoro-L-arabinofuranosyl)-5-methyluracil (-[ 18F]FMAU) are currently being pursued clinically (Scher, B. et al., Eur J Nucl Med Mol Imaging 2007, 34, 45-53; Rinnab, L et al., BJU Int 2007, 100, 786,793; Reske, SN et al., J Nucl Med 2006, 47, 1249-1254; Zophel, K., Kotzerke, J. Eur J Nucl Med Mol Imaging 2004, 31, 756-759; Vees, H. et al., BJU Int 2007, 99, 1415-1420; Larson, SM et al., J Nucl Med 2004, 45, 366-373; Schuster, DM et al., J Nucl Med 2007, 48, 56-63; Tehrani, OS et al., J Nucl Med 2007, 48, 1436-1441). Each acts by a different mechanism and provides certain benefits, e.g. 11 C]choline has low urinary excretion, and disadvantages such as the short physical half-life of the positron-emitting radionuclide.

[0004] It is well known that tumors can express unique proteins associated with their malignant phenotype or overexpress normal constitutive proteins in greater numbers than normal cells. The expression of different proteins on the surface of tumor cells offers the opportunity to diagnose and characterize the disease by exploring the phenotypic identity and biochemical composition and activity of the tumor. Radioactive molecules that selectively bind to specific tumor cell surface proteins offer an attractive route to image and treat tumors under non-invasive conditions. A promising new series of low molecular weight imaging agents targets prostate-specific membrane antigen (PSMA) (Mease RC et al., Clin Cancer Res. 2008, 14, 3036-3043; Foss, CA et al., Clin Cancer Res 2005, 11, 4022-4028; Pomper, MG et al., Mol Imaging 2002, 1, 96-101; Zhou, J. et al., Nat Rev Drug Discov 2005, 4, 015-1026; WO 2013 / 022797).

[0005] PSMA is a transmembrane 750 amino acid type II glycoprotein with abundant and restricted expression on the surface of PCa, especially in androgen-independent advanced and metastatic disease (Schulke, N. et al., Proc Natl Acad Sci USA 2003, 100, 12590-12595). The latter is important because almost all PCa becomes androgen-independent over time. PSMA has the criteria for a promising target for therapy (Schulke, N. et al., Proc. Natl. Acad. Sci. USA 2003, 100, 12590-12595). The PSMA gene is located on the short arm of chromosome 11 and functions as both a folate hydrolase and a neuropeptidase. It has a neuropeptidase function equivalent to glutamate carboxypeptidase II (GCPII), has been termed "brain PSMA", and can modulate glutamatergic transmission by cleaving N-acetylaspartylglutamate (NAAG) to N-acetylaspartate (NAA) and glutamate (Nan, F. et al., J Med Chem 2000, 43, 772-774). Up to 10 per cancer cell 6 There are several PSMA molecules, further suggesting it as an ideal target for imaging and therapy using radionuclide-based techniques (Tasch, J. et al., Crit Rev Immunol 2001, 21, 249-261).

[0006] A radioimmunoconjugate of anti-PSMA monoclonal antibody (mAb) 7E11, known as PROSTASCINT® scan, is currently used to diagnose prostate cancer metastasis and recurrence. However, this agent tends to produce images that are difficult to interpret (Lange, PH PROSTASCINT scan for staging prostate cancer. Urology 2001, 57, 402-406; Haseman, MK et al., Cancer Biother Radiopharm 2000, 15, 131-140; Rosenthal, SA et al., Tech Urol 2001, 7, 27-37). More recently, monoclonal antibodies that bind to the extracellular domain of PSMA have been developed, radiolabeled, and shown to accumulate in PSMA-positive prostate tumor models in animals. However, diagnosis and tumor detection using monoclonal antibodies is limited by the poor penetration of monoclonal antibodies in solid tumors.

[0007] Selective targeting of cancer cells with radiopharmaceuticals, either for imaging or therapeutic purposes, is challenging. 111 In, 90 Y, 68 Ga, 177 Lu, 99m Tc, 123 I and 131 It is known that certain compounds are useful for radioimaging or cancer radiotherapy, including I. Recently, some compounds containing glutamate-urea-glutamate (GUG) or glutamate-urea-lysine (GUL) recognition elements linked to a radionuclide-ligand conjugate have been shown to exhibit high affinity for PSMA.

[0008] In WO 2015 / 055318, new imaging agents with improved tumor targeting properties and pharmacokinetics were described. These compounds contain a motif that specifically binds to the cell membrane of cancerous cells, the motif being the glutamate-urea-lysine motif Prostate-specific membrane antigen (PSMA) described above. Preferred molecules described in WO 2015 / 055318 further contain a linker that binds to the carboxylic acid group of DOTA as a chelating agent via an amide bond. Some of these compounds have been shown to be promising agents for the specific targeting of prostate tumors. The compounds are: 177 Lu (for therapeutic purposes) or 68 It is labeled with Ga (for diagnostic purposes) to allow visualization and targeting of prostate cancer for radiotherapy purposes.

[0009] However, in therapeutic applications of radiolabeled PSMA inhibitors, organs with physiological PSMA expression proved to be dose-limiting and therefore the success of the treatment was minimized. In particular, the high uptake of radiolabeled PSMA inhibitor material by the renal and salivary glands is noteworthy, which generates considerable side effects in the case of therapeutic applications. Attempts to improve the uptake of PSMA inhibitors by the kidney led to the development of PSMA-617 [Benesova, M. et al. (2016) J Med Chem 59, 1761-75], a compound already used clinically with 177Lu or 225Ac for internal radiotherapy of prostate cancer. However, reduction of uptake by salivary and lacrimal glands has still not been achieved and is still described as crucial and dose-limiting in early clinical work. In a first-in-human study with 225Ac-PSMA-617, two patients with very advanced and late-stage disease showed complete remission. In both patients, PSA values ​​fell below the limit of detectability. Concomitant diagnostic records using 68Ga-PSMA-11 confirmed the complete response.

[0010] As already mentioned above, the strong accumulation of PSMA ligand in salivary gland and lacrimal gland, which is described in many papers, leads to significant side effects.Salivary gland and lacrimal gland are severely and partially irreversibly damaged, especially during alpha treatment with 225Ac.As a result, xerostomia symptoms represent, for example, dose-limiting side effects. Summary of the Invention [Problem to be solved by the invention]

[0011] Thus, there remains a need for improved PSMA ligands that provide advantageous options for the detection, treatment and management of PSMA-expressing cancers, particularly prostate cancer, and that preferably exhibit fewer side effects on the salivary and / or lacrimal glands, in particular exhibit reduced uptake by the salivary and / or lacrimal glands, thereby reducing the respective side effects. [Means for solving the problem]

[0012] The solution of said object is achieved by providing the embodiments characterized in the claims. The inventors have found new compounds that are useful and advantageous radiopharmaceuticals and can be used as tracers, imaging agents in nuclear medicine and for the treatment of various disease states of PSMA-expressing cancers, in particular prostate cancer. These compounds are described in more detail below.

[0013] In particular, the present invention relates to a compound represented by formula (1)

[0014] [ka] (In the formula, R 1 is H or -CH3, preferably H; R 2 , R 3 and R 4 are each independently selected from the group consisting of -CO2H, -SO2H, -SO3H, -OSO3H, -PO2H, -PO3H and -OPO3H2; Q 1is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl, and heteroaryl; Q 2is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl and alkylheteroaryl; A is selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (=DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 1, 4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonane-1-yl)pentanedioic acid (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononanephosphinic acid (TRAP), 1,4,7-triazacyclononanephosphinic acid (TRAP), Rononane phosphinic acid (TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO), 3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (=PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[ X is a chelator residue derived from a chelator selected from the group consisting of 5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A), p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA); 1 , X 2 , Y 1 , Y 2 , Z1 and Z 2 are each independently a charged amino acid; q is an integer from 0 to 3; n, m, and p are each independently an integer from 0 to 9; n1, n2, m1, m2, p1, and p2 are each independently an integer from 0 to 3; n1+n2>0, m1+m2>0, and p1+p2>0; and n+m+p>0. or a pharma- ceutically acceptable salt or solvate thereof.

[0015] Furthermore, the present invention provides a method for producing a (a) Radionuclides, and (b) a compound as described above or below or a pharma- ceutically acceptable salt or solvate thereof; The present invention relates to a complex comprising:

[0016] Furthermore, the present invention relates to a pharmaceutical composition comprising a compound as described above or below, or a pharma- ceutically acceptable salt or solvate thereof as described above or below, or a complex as described above or below.

[0017] Furthermore, the present invention relates to a compound as described above or below or a pharma- ceutically acceptable salt or solvate thereof, or a complex as described above or below, or a pharmaceutical composition as described above or below, for use in treating or preventing PSMA-expressing cancer, in particular prostate cancer and / or metastasis thereof.

[0018] X 1 , X 2 , Y 1 , Y 2 , Z 1 and Z 2 As stated above, X 1 , X 2 , Y 1 , Y 2 , Z 1 and Z 2are, independently of each other, charged amino acids. The term "charged amino acid" as used herein refers to an amino acid that contains a side chain that is negatively charged (i.e., deprotonated) or positively charged (i.e., protonated) in aqueous solution at physiological pH. The term should be understood to include naturally occurring and non-naturally occurring charged amino acids and to include all stereoisomers of these amino acids, e.g., enantiomers and diastereomers. Most preferably, the amino acid is an alpha amino acid. With regard to chirality, L-amino acids are preferred.

[0019] The term "negatively charged amino acid" includes, but is not limited to, aspartic acid, glutamic acid, cysteic acid, homocysteic acid, and homoglutamic acid, homoglutamic acid, sulfonic acid derivatives of Cys, cysteic acid, homocysteic acid, aspartic acid (D), and glutamic acid (E). More preferably, the negatively charged amino acid is aspartic acid or glutamic acid (E).

[0020] The term "sulfonic acid derivative of Cys" preferably refers to an amino acid having the structure HO2C-CH(NH2)-CH-S(OH)(=O)2, CAS number: 498-40-8.

[0021] The term "positively charged amino acid" includes, but is not limited to, arginine, lysine, histidine homoarginine, 3 and 4 substituted arginine analogs, N(delta)-methyl-arginine (delta MA), canavanine, substituted analogs of canavanine, α-amino-β-guanidinopropionic acid, γ-guanidinobutyric acid, citrulline, 3-guanidinopropionic acid, 4-{[amino(imino)methyl]amino}butanoic acid, 6-{[amino(imino)methyl]amino}hexanoic acid, 2-amino-3-guanidinopropionic acid, arginine hydroxamate, agmatine (CAS number: 2482-00-0), and NG-methyl-arginine. The most preferred positively charged amino acids are lysine (K), histidine (H) and arginine (R).

[0022] integers n, m and p, n1, n2, m1, m2, p1, p2 As described above, n, m and p are each independently an integer from 0 to 9, with the proviso that n+m+p>0.

[0023] Furthermore, n1, n2, m1, m2, p1 and p2 are each independently an integer of 0 to 3, where n1+n2>0, m1+m2>0, and p1+p2>0.

[0024] Therefore, n1+n2 is at least 1, m1+m2 is at least 1, and p1+p2 is at least 1. Furthermore, n+m+p is at least 1.

[0025] Thus, a compound of formula 1 contains at least one charged amino acid. If (n1+n2)n + (m1+m2)m + (p1+p2)p = 1, then the compound is X 1 , X 2 , Y 1 , Y 2 , Z 1 or Z 2 It contains exactly one charged amino acid, either

[0026] Preferably, n1, n2, m1, m2, p1, p2 are each independently 0 or 1.

[0027] In particular, the compound comprises at least two charged amino acids. Thus, (n1+n2)n + (m1+m2)m + (p1+p2)p is preferably at least 2, and n1, n2, m1, m2, p1, and p2 are more preferably each independently 0 or 1. More preferably, (n1+n2)n + (m1+m2)m + (p1+p2)p is an integer between 2 and 20, preferably between 2 and 10, more preferably between 4 and 8, more preferably 6, and most preferably, n1, n2, m1, m2, p1, and p2 are each independently 0 or 1.

[0028] If the compound comprises more than one amino acid, these amino acids are preferably linked directly to each other via amide bonds, thus forming a peptidic backbone. Thus, preferably, (n1+n2)n>1 and (m1+m2)m+(p1+p2)p=0, or (m1+m2)m>1 and (n1+n2)n+(p1+p2)p=0, or (p1+p2)p>1 and (m1+m2)m+(n1+n2)n=0. [Brief description of the drawings]

[0029] [Figure 1] Figure 1 shows a pharmacokinetic study using small animal PET imaging. Time activity curves for the kidney following injection of 0.5 nmol of 68Ga-labeled compound up to 60 min pi in LNCaP tumor-bearing athymic nude mice (right trunk). SUV = standard uptake value. [Figure 2-1] Figure 1 shows a pharmacokinetic study using small animal PET imaging. Time activity curves for tumor and muscle following injection of 0.5 nmol of each 68Ga-labeled compound X (see Table 5) up to 60 min pi in LNCaP tumor-bearing athymic nude mice (right trunk). SUV = standard uptake value. [Figure 2-2] As shown in [Figure 2-1]. [Figure 2-3] As shown in [Figure 2-1]. [Figure 2-4] As shown in [Figure 2-1]. [Figure 2-5] As shown in [Figure 2-1]. [Figure 2-6] As shown in [Figure 2-1]. [Diagram 2-7] As shown in [Figure 2-1]. [Figure 2-8] As shown in [Figure 2-1]. [Figure 2-9] As shown in [Figure 2-1]. [Figure 2-10] As shown in [Figure 2-1]. [Figure 3-1]

[0023] Figure 1 shows small animal PET imaging studies. Whole-body maximum intensity projections of 0.5 nmol of each 68Ga-labeled compound X (see Table 6) in LNCaP tumor-bearing athymic nude mice (right trunk) at 60 minutes pi (Figure XA) and 120 minutes pi (Figure XB) obtained from small animal PET imaging. [Figure 3-2] As shown in [Figure 3-1]. [Figure 3-3] As shown in [Figure 3-1]. [Diagram 3-4] As shown in [Figure 3-1]. [Figure 3-5] As shown in [Figure 3-1]. [Diagram 3-6] As shown in [Figure 3-1]. [Diagram 3-7] As shown in [Figure 3-1]. [Diagram 3-8] As shown in [Figure 3-1]. [Diagram 3-9] As shown in [Figure 3-1]. [Figure 3-10] As shown in [Figure 3-1]. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Preferred embodiment 1a: According to a first preferred embodiment, (n1+n2)n>1, where n1 is preferably 0 or 1 and n2 is preferably 0 or 1.

[0031] More preferably, (n1+n2)n is 2 to 10, more preferably 4 to 8, and more preferably 6, n1 is preferably 0 or 1, and n2 is preferably 0 or 1. This is the case, for example, of X 1 and X 2 Combinations of, for example, ((X 1 )1(X 2 )0)6, ((X 1 )0(X 2 )1)6, as well as combinations that include both amino acids, such as ((X 1 )1(X 2)1)3 should be understood to include these.

[0032] According to this embodiment, n1 and n2 are preferably both 1 and n is 2 to 10, more preferably 2 to 5, more preferably 3. According to an alternatively preferred embodiment, n1 and n2 are preferably both 1 and n is preferably 4.

[0033] Preferably, X according to embodiment (1a) 1 Or X 2 At least one of X is a negatively charged amino acid, 1 and X 2 At least one of is a positively charged amino acid.

[0034] More preferably, X 1 and X 2 At least one of X is histidine (H), 1 and X 2 At least one of the building blocks (X 1 ) n1 (X 2 ) n2 ) n is structure (HE) n or (EH) n , preferably (EH) n has.

[0035] More preferably, according to this first embodiment, (m1+m2)m + (p1+p2)p = 0. Thus, according to this preferred embodiment, the compound preferably has the structure (1a):

[0036] [ka] and a building block ((X 1 ) n1 (X 2 ) n2 ) n More preferably, the structure (HE) n or (EH) n, more preferably (EH) n and n is most preferably 2 to 10, more preferably 2 to 5, more preferably 3 or 4. Thus, according to a preferred embodiment, the building block ((X 1 ) n1 (X 2 ) n2 ) n has the structure (HE)3 or (EH)3. According to a further preferred embodiment, the building block ((X 1 ) n1 (X 2 ) n2 ) n is structure (HE)4 or (EH) 4、 Preferably it has (HE)4.

[0037] Therefore, the following structure (1a_1)

[0038] [ka] is particularly preferred.

[0039] Furthermore, the following structure (1a_2)

[0040] [ka] is preferred.

[0041] Furthermore, the following structure (1a_3)

[0042] [ka] is particularly preferred.

[0043] According to a preferred embodiment, the compound is selected from the group consisting of compounds (1a-1), (1a-2) and (1a-3), more preferably (1a-1) or (1a-3).

[0044] As outlined above, the amino acids E and H preferably have the L configuration.

[0045] Preferred embodiment 1aa According to a further preferred embodiment, (n1+n2)n>1, where n1 is preferably 0 or 1 and n2 is preferably 0 or 1.

[0046] More preferably, (n1+n2)n is 2 to 10, more preferably 4 to 8, and more preferably 6, n1 is preferably 0 or 1, and n2 is preferably 0 or 1. This is the case, for example, of X 1 and X 2 Combinations of, for example, ((X 1 )1(X 2 )0)6, ((X 1 )0(X 2 )1)6, as well as combinations that include both amino acids, such as ((X 1 )1(X 2 )1)3 should be understood to include these.

[0047] According to this embodiment, n1 is preferably 1, n2 is preferably 0, and n is preferably 3 or 4, preferably 3.

[0048] X 1 is preferably a negatively charged amino acid or a positively charged amino acid, more preferably X 1 is histidine (H) or glutamic acid (E), more preferably histidine.

[0049] More preferably, according to this embodiment (1aa), (m1+m2)m + (p1+p2)p = 0. Thus, according to this preferred embodiment, the compound preferably has the structure (1aa):

[0050] [ka] and a building block ((X 1 ) n1 ) n (H) n Or (E) n, more preferably (H)3 or (E)3 or (H)4 or (E)4, in particular (H)3 or (E)3.

[0051] Therefore, the following structure (1aa_1)

[0052] [ka] is particularly preferred.

[0053] In addition, the following structure (1aa_2)

[0054] [ka] is particularly preferred.

[0055] Thus, according to a particularly preferred embodiment, the compound has a structure selected from the group consisting of structures (1a_1), (1a_2), (1a_3), (1aa_2) and (1aa-1), more preferably a structure selected from the group consisting of structures (1a_1), (1a_3), (1aa_2) and (1aa_1), more preferably the structure is (1a_1) or (1a_3).

[0056] As outlined above, the amino acids E and H preferably have the L configuration.

[0057] Preferred embodiment 1b: According to a second preferred embodiment, (m1+m2)n>1, where m1 is preferably 0 or 1 and m2 is preferably 0 or 1.

[0058] More preferably, (m1+m2)m is 2 to 10, more preferably 4 to 8, and more preferably 6, m1 is preferably 0 or 1, and m2 is preferably 0 or 1. This is the case, for example, of Y 1 and Y 2 Combinations of, for example, ((Y 1 )1(Y 2 )0)6, ((Y1 )0(Y 2 )1)6 and ((Y 1 )1(Y 2 )1)3 should be understood to include these.

[0059] According to embodiment (1b), m1 and m2 are preferably both 1 and m is 2-10, more preferably 2-5, more preferably 3.

[0060] Preferably, at least one of Y1 or Y2 in this embodiment is a negatively charged amino acid, and at least one of Y1 and Y2 is a positively charged amino acid.

[0061] More preferably, Y 1 and Y 2 At least one of is histidine (H), and Y 1 and Y 2 is glutamic acid (E). More preferably, at least one of the building blocks (Y 1 ) m1 (Y 2 ) m2 ) m is structure (HE) m or (EH) m , preferably (EH) m has.

[0062] More preferably, according to embodiment (1b), (n1+n2)n + (p1+p2)p = 0. Thus, according to this preferred embodiment, the compound preferably has the structure (1b):

[0063] [ka] and the building block ((Y 1 ) m1 (Y 2 ) m2 ) m More preferably, the structure (HE) m or (EH) m , more preferably (EH) mand m is most preferably 2 to 10, more preferably 2 to 5, and more preferably 3.

[0064] Therefore, the following structure (1b_1)

[0065] [ka] is particularly preferred.

[0066] As outlined above, the amino acids E and H preferably have the L configuration.

[0067] Preferred embodiment 1bb: According to a further preferred embodiment, (m1+m2)n>1, where m1 is preferably 0 or 1 and m2 is preferably 0 or 1.

[0068] More preferably, (m1+m2)m is 2 to 10, more preferably 4 to 8, and more preferably 6, m1 is preferably 0 or 1, and m2 is preferably 0 or 1. This is the case, for example, of Y 1 and Y 2 Combinations of, for example, ((Y 1 )1(Y 2 )0)6, ((Y 1 )0(Y 2 )1)6 and ((Y 1 )1(Y 2 )1)3 should be understood to include these.

[0069] According to embodiment (1bb), m1 is preferably 1, m2 is 0, and m is preferably 2-10, more preferably 2-5, more preferably 3.

[0070] Y 1 is preferably a negatively charged amino acid or a positively charged amino acid, more preferably Y 1 is histidine (H) or glutamic acid (E), more preferably histidine.

[0071] More preferably, according to embodiment (1b), (n1+n2)n + (p1+p2)p = 0. Thus, according to this preferred embodiment, the compound preferably has the structure (1bb):

[0072] [ka] and the building block ((Y 1 ) m1 ) m More preferably, the structure (H) m Or (H) m and m is most preferably 2 to 10, more preferably 2 to 5, and more preferably 3.

[0073] Therefore, the following structure (1bb_1)

[0074] [ka] is preferred.

[0075] Therefore, the following structure (1bb_2)

[0076] [ka] is preferred.

[0077] As outlined above, the amino acids E and H preferably have the L configuration.

[0078] Preferred embodiment 1c: According to a third preferred embodiment, (p1+p2)p>1, p1 is preferably 0 or 1 and p2 is preferably 0 or 1.

[0079] More preferably, (p1+p2)p is 2 to 10, more preferably 4 to 8, and more preferably 6, p1 is preferably 0 or 1, and p2 is preferably 0 or 1. This is, for example, Z 1 and Z.Y. 2Combinations of, for example, ((Z 1 )1(Z 2 )0)6, ((Z 1 )0(Z 2 )1)6 and ((Z 1 )1(Z 2 )1)3 should be understood to include these.

[0080] According to embodiment (1c), p1 and p2 are preferably both 1 and p is 2-10, more preferably 2-5, more preferably 3.

[0081] Preferably, Z in this embodiment 1 or Z 2 At least one of Z is a negatively charged amino acid, 1 and Z 2 At least one of is a positively charged amino acid.

[0082] More preferably, Z 1 and Z 2 At least one of is histidine (H), and Z 1 and Z 2 At least one of the building blocks (Z 1 ) p1 (Z 2 ) p2 ) p is structure (HE) p or (EH) p , preferably (EH) p has.

[0083] More preferably, according to embodiment (1c), (n1+n2)n + (m1+m2)m = 0. Thus, according to this preferred embodiment, the compound preferably has the structure (1c):

[0084] [ka] and the building block ((Z 1 ) p1 (Z 2 ) p2 )p More preferably, the structure (HE) p or (EH) p , more preferably (EH) p and p is most preferably 2 to 10, more preferably 2 to 5, and more preferably 3.

[0085] Therefore, the following structure (1c_1)

[0086] [ka] is particularly preferred.

[0087] As outlined above, the amino acids E and H preferably have the L configuration.

[0088] Preferred embodiment 1cc: According to a further preferred embodiment, (p1+p2)p>1, where p1 is preferably 0 or 1 and p2 is preferably 0 or 1.

[0089] More preferably, (p1+p2)p is 2 to 10, more preferably 4 to 8, and more preferably 6, p1 is preferably 0 or 1, and p2 is preferably 0 or 1. This is, for example, Z 1 and Z.Y. 2 Combinations of, for example, ((Z 1 )1(Z 2 )0)6, ((Z 1 )0(Z 2 )1)6 and ((Z 1 )1(Z 2 )1)3 should be understood to include these.

[0090] According to embodiment (1cc), p1 is preferably 1, p2 is 0, and p is preferably 2-10, more preferably 2-5, more preferably 3.

[0091] Z 1 is preferably a negatively charged amino acid or a positively charged amino acid, more preferably Z 1is histidine (H) or glutamic acid (E), more preferably histidine.

[0092] More preferably, according to embodiment (1c), (n1+n2)n + (m1+m2)m = 0. Thus, according to this preferred embodiment, the compound preferably has the structure (1cc):

[0093] [ka] and the building blocks (Z 1 ) p More preferably, the structure (H) p Or (E) p and p is most preferably 2 to 10, more preferably 2 to 5, and more preferably 3.

[0094] Therefore, the following structure (1cc_1)

[0095] [ka] is preferred.

[0096] In addition, the following structure (1cc_2)

[0097] [ka] is preferred.

[0098] As outlined above, the amino acids E and H preferably have the L configuration.

[0099] R 1 , R 2 , R 3 and R 4 R 1 is H or -CH3, preferably H.

[0100] R 2 , R 3 and R 4are each independently selected from the group consisting of -CO2H, -SO2H, -SO3H, -OSO3H, -PO2H, -PO3H and -OPO3H2, more preferably R 2 , R 3 and R 4 is CO2H.

[0101] Q1 Q 1 is preferably selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl and heteroaryl.

[0102] The term "aryl" as used in the present context of the present invention refers to optionally substituted 5- and 6-membered aromatic rings, as well as substituted or unsubstituted polycyclic aromatic groups (aryl groups), such as tricyclic or bicyclic aryl groups. Optionally substituted phenyl or naphthyl groups may be mentioned as examples. Polycyclic aromatic groups may also contain non-aromatic rings.

[0103] The term "alkylaryl", as used in the present context of the present invention, refers to an aryl group in which at least one proton has been replaced with an alkyl group (alkyl-aryl-).

[0104] The term "arylalkyl", as used in this context of the present invention, refers to an aryl group linked via an alkyl group (aryl-alkyl-).

[0105] The term "heteroaryl" as used in this context of the present invention refers to optionally substituted 5- and 6-membered aromatic rings containing one or more, e.g. 1 to 4, e.g. 1, 2, 3 or 4 heteroatoms in the ring system, as well as substituted or unsubstituted polycyclic aromatic groups, e.g. tricyclic or bicyclic aryl groups. If more than one heteroatom is present in the ring system, the at least two heteroatoms present may be the same or different. Suitable heteroaryl groups are known to those skilled in the art. The following heteroaryl residues may be mentioned by way of non-limiting example: benzodioxolyl, pyrrolyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, methylenedioxyphenylyl, naphthyridinyl, quinolinyl, isoquinolinyl, indolyl, benzofuranyl, purinyl, benzofuranyl, deazapurinyl, pyridazinyl and indolizinyl.

[0106] The term "alkylheteroaryl" as used in the present context of the present invention refers to a heteroaryl group in which at least one proton has been replaced with an alkyl group (alkyl-heteroaryl-).

[0107] The term "heteroarylalkyl", as used in the present context of the present invention, refers to a heteroaryl group linked via an alkyl group (heteroaryl-alkyl-).

[0108] The term "cycloalkyl" denotes in the context of the present invention optionally substituted cyclic alkyl residues, which may be monocyclic or polycyclic groups. Optionally substituted cyclohexyl may be mentioned as a preferred example of a cycloalkyl residue.

[0109] The term "heterocycloalkyl", as used in this context of the present invention, designates optionally substituted cyclic alkyl residues having at least one heteroatom, such as O, N or S, in the ring, which may be monocyclic or polycyclic groups.

[0110] The term "substituted cycloalkyl residue" or "cycloheteroalkyl" as used in the present context of the present invention refers to a cycloalkyl residue or a cycloheteroalkyl residue in which at least one H has been replaced with a suitable substituent.

[0111] Preferably, Q1 comprises a residue selected from the group consisting of naphthyl, phenyl, biphenyl, indolyl, benzothiazolyl, naphthylmethyl, phenylmethyl, biphenylmethyl, indolylmethyl and benzothiazolylmethyl, more preferably Q 1 teeth,

[0112] [ka] Q is selected from the group consisting of 1 is most preferably

[0113] [ka] It is.

[0114] Thus, the compound preferably has the structure

[0115] [ka] and more preferably has a structure selected from the following groups:

[0116] [ka] has.

[0117] Q2 As stated above, Q 2 is preferably selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl and alkylheteroaryl.

[0118] The term "aryl" as used in the present context refers to optionally substituted 5- and 6-membered aromatic rings, as well as substituted or unsubstituted polycyclic aromatic groups (aryl groups), such as tricyclic or bicyclic aryl groups (-Ar-). Optionally substituted phenyl or naphthyl groups may be mentioned as examples. Polycyclic aromatic groups, in the present context of the present invention, may also contain non-aromatic rings, aryl groups.

[0119] The term "alkylaryl", as used in the present context of the present invention, refers to an aryl group in which at least one proton has been replaced with an alkyl group (-alkyl-aryl-) and which is linked via the alkyl group to a -CH2- group and via the aryl group to a carbonyl group.

[0120] The term "arylalkyl", as used in this context of the present invention, refers to an aryl group linked via an alkyl group to a carbonyl group and via an aryl group to a -CH2- group (-aryl-alkyl-).

[0121] The term "heteroaryl" (-heteroaryl-) as used in this context of the present invention means optionally substituted 5- and 6-membered aromatic rings containing one or more, e.g. 1 to 4, e.g. 1, 2, 3 or 4 heteroatoms in the ring system, as well as substituted or unsubstituted polycyclic aromatic groups, e.g. tricyclic or bicyclic aryl groups. If more than one heteroatom is present in a ring system, the at least two heteroatoms present may be the same or different. Suitable heteroaryl groups are known to those skilled in the art. The following heteroaryl residues may be mentioned by way of non-limiting example: benzodioxolyl, pyrrolyl, furanyl, thiophenyl, thiazolyl, isothiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrazinyl, pyridazinyl, benzoxazolyl, benzodioxazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, methylenedioxyphenylyl, naphthyridinyl, quinolinyl, isoquinolinyl, indolyl, benzofuranyl, purinyl, benzofuranyl, deazapurinyl, pyridazinyl and indolizinyl.

[0122] The term "alkylheteroaryl", as used in the present context of the present invention, refers to an aryl group in which at least one proton has been replaced with an alkyl group (-alkyl-heteroaryl-) and which is linked via the alkyl group to a -CH2- group and via the heteroaryl group to a carbonyl group.

[0123] The term "heteroarylalkyl", as used in this context of the present invention, refers to a heteroaryl group that is linked via an alkyl group to a carbonyl group and via a heteroaryl group to a -CH2- group (-aryl-alkyl-).

[0124] The term "cycloalkyl" (-cycloalkyl-) denotes in the context of the present invention optionally substituted cyclic alkyl residues, which may be monocyclic or polycyclic groups. Optionally substituted cyclohexyl may be mentioned as a preferred example of a cycloalkyl residue.

[0125] The term "heterocycloalkyl", as used in this context of the present invention, designates optionally substituted cyclic alkyl residues having at least one heteroatom, such as O, N or S, in the ring, which may be monocyclic or polycyclic groups.

[0126] The term "substituted cycloalkyl residue" or "cycloheteroalkyl" as used in the present context of the present invention refers to a cycloalkyl residue or a cycloheteroalkyl residue in which at least one H has been replaced with a suitable substituent.

[0127] Preferably, Q 2 is an aryl group or a cycloalkyl group, more preferably

[0128] [ka] and most preferably

[0129] [ka] It is.

[0130] Q 2 It should be understood that any stereoisomer of Q is possible and is included. 2 but,

[0131] [ka] When the ring structure is, this should be understood to include cis as well as trans isomers, with the trans isomer being particularly preferred.

[0132] The integer q is an integer from 0 to 3, and most preferably q is 0 or 1, and more preferably 1.

[0133] Chelating agent residue A A is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (=DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid, (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononanephosphinic acid (TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO), 3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (=PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A) p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA).

[0134] The term "chelator residue" and typically further the term "chelator residue derived from a chelator selected from the group" refers to a chelator as described above, and thus typically defined as a "group", which is capable of reacting with the compound (I) via a suitable functional group, preferably via the former carboxylic acid group of the chelator.

[0135] [ka] is shown to mean that the chelator is linked to the N-terminal end of the chelator, thereby forming an amide bond between the chelator and compound (I). If (n1+n2)n > 0, then the chelator is thus linked to the N-terminal end of the amino acid building block H-((X 1 ) n1 (X 2 ) n2 ) n If (n1+n2)n=0 and q is >0, the chelator is attached to the N-terminal group of the building block H-(NH-CH2-Q2-C(=O)) q If (n1+n2)n = 0, q = 0, and (m1+m2)m > 0, then the chelator is an amino acid building block H-((Y 1 ) m1 (Y 2 ) m2 ) m If (n1+n2)n = 0, q = 0, and (m1+m2)m = 0, then the chelator is an amino acid building block H-(NH-CH(Q 1 )-C(=O))-, thereby forming an amide bond.

[0136] Preferably, A is

[0137] [ka] is a chelator residue having a structure selected from the group consisting of:

[0138] Most preferably, A is the structure

[0139] [ka] has.

[0140] Complex As described above, the present invention provides a method for producing a medicament for the treatment of a cancer, comprising: (a) Radionuclides, and (b) a compound as described above or below or a pharma- ceutically acceptable salt or solvate thereof; The present invention also relates to a complex comprising:

[0141] Typical pharmaceutically acceptable salts include those prepared by the reaction of the compounds of the present invention with pharmaceutically acceptable mineral or organic acids or organic or inorganic bases.These salts are known as acid addition salts and base addition salts.The acids commonly used to form acid addition salts are inorganic acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc., and organic acids, such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, etc. Examples of such pharma- ceutically acceptable salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyrate, butylate ... The preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid. Salts of amine groups may also include quaternary ammonium salts in which the amino nitrogen bears a suitable organic group, such as an alkyl, alkyl ester, alkyl ester, alkyl ester, alkyl ester, alkyl ester, alkyl ester, alkyl ester, aryl ... Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonia hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like. The potassium and sodium salt forms are particularly preferred. It should be recognized that the particular counter ion forming a part of any salt of this invention is usually not of critical nature, so long as the salt as a whole is pharmacologically acceptable and so long as the counter ion does not contribute any undesirable qualities to the salt as a whole.

[0142] The term "pharmaceutically acceptable solvate" also encompasses suitable solvates of the compounds of the invention, where the compound, upon combination with a solvent such as water, methanol, ethanol, DMSO, acetonitrile, or mixtures thereof, forms a suitable solvate, such as the corresponding hydrate, methanolate, ethanolate, DMSO solvate, or acetonitrile.

[0143] Radionuclides Depending on whether the compounds of the invention are to be used as radioimaging agents or radiopharmaceuticals, different radionuclides are complexed to the chelating agent.

[0144] The complexes of the present invention may contain one or more radionuclides, preferably one radionuclide. These radionuclides are preferably suitable for use as radioimaging agents or as therapeutic agents for the treatment of proliferating cells, such as PSMA-expressing cancer cells, in particular PSMA-expressing prostate cancer cells. According to the present invention, they are called "metal complexes" or "radiopharmaceuticals".

[0145] A preferred imaging method is positron emission tomography (PET) or single photon emission computed tomography (SPECT).

[0146] Preferably, the at least one radionuclide is 89 Zr, 44 Sc, 111 ln, 90 Y,66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Cu, 67 Cu, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 161 Tb, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac, 230 U, 223 Ra, 165 Er, 52 Fe, 59 Fe, and Pb radionuclides (e.g., 203 Pb and 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 Pb, 198 Pb, 197 Pb).

[0147] More preferably, the at least one radionuclide is 90 Y, 68 Ga, 177 Lu, 225 Ac and 213 More preferably, the radionuclide is selected from the group consisting of: 177 Lu or 225 It is Ac.

[0148] Preferably, the radionuclide has a half-life of at least 30 minutes, more preferably at least 1 hour, more preferably at least 12 hours, even more preferably at least 1 day, most preferably at least 5 days, yet more preferably, the radionuclide has a half-life of at most 1 year, more preferably at most 6 months, even more preferably at most 1 month, even more preferably at most 14 days. Thus, preferably, the radionuclide has a half-life of 30 minutes to 1 year, more preferably 12 hours to 6 months, even more preferably 1 day to 1 month, most preferably 5 days to 14 days.

[0149] Preferably, the radionuclide is an α- and / or β-emitter, ie the radionuclide preferably emits α-particles (α-emitters) and / or β-radiation (β-emitters).

[0150] Preferably, when the radionuclide is an α-emitter, the α-particles have an energy of from 1 to 10 MeV, more preferably from 2 to 8 MeV, most preferably from 4 to 7 MeV.

[0151] Preferably, when the radionuclide is a β-emitter, the β-radiation has an energy of 0.1 to 10 MeV, more preferably 0.25 to 5 MeV, most preferably 0.4 to 2 MeV.

[0152] Preferred radionuclides that emit β-radiation are 90 Y, 177 Lu, 59 Fe, 66 Cu, 67 Cu, 161 Tb, 153 Sm, 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 A highly preferred β-emitting radionuclide is selected from the group consisting of: 177 Lu or 90 Y, most preferably 177 Lu. Preferably, in this case, the use is diagnostic or therapeutic.

[0153] Preferred radionuclides that emit α-radiation are, for example: 213 Bi, 225 Ac, 149 Tb, 230 U and 223 Ra, 213 Bi, 230 More preferably, the radionuclide is selected from the group consisting of: 225 Ac and / or 213 Bi. Highly preferred radionuclides that emit α-radiation are e.g. 225 Ac. Preferably, in this case, the use is therapeutic.

[0154] According to a further embodiment, the radionuclide is a positron emitter. In this case, the radionuclide is preferably 89 Zr, 44 Sc, 66 Ga, 68 Ga and 64 Cu. In this case, the use is preferably PET diagnosis.

[0155] According to a further preferred embodiment, the radionuclide is a gamma emitter. In this case, the radionuclide is preferably 111 In, 67 Ga, 99m Tc, 155 Tb, 165 Er and 203 Pb. In this case, the use is preferably in SPECT diagnosis.

[0156] According to a further preferred embodiment, the radionuclide emits Auger electrons and preferably decays by electron capture. In this case, the radionuclide preferably has 67 Ga, 155 Tb, 153 Gd, 165 Er and 203 Pb. In this case, the use is preferably therapeutic.

[0157] Pharmaceutical Compositions As described above, the present invention also relates to a pharmaceutical composition comprising a compound as described above or below or a complex as described above or below. It should be understood that the pharmaceutical composition preferably comprises a therapeutically effective amount of said compound and / or said complex, respectively. The pharmaceutical composition may further comprise at least one organic or inorganic solid or liquid and / or at least one pharma- ceutically acceptable carrier.

[0158] The terms "medicament" and "pharmaceutical composition" as used herein refer to the compounds and / or complexes of the present invention and, optionally, one or more pharma- ceutically acceptable carriers, i.e. excipients. The compounds of the present invention may be formulated as pharma- ceutically acceptable salts, which are described herein above. The pharmaceutical compositions are preferably administered locally (e.g., intratumorally), topically or systemically. Suitable routes of administration traditionally used for drug administration are oral, intravenous or parenteral administration, as well as inhalation. The preferred route of administration is parenteral administration. "Parenteral administration route" refers to modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intrathecal and intrasternal injection and infusion. Preferably, administration is by intravenous administration or infusion. However, depending on the nature and mode of action of the compound, the pharmaceutical compositions can be administered by other routes as well.

[0159] Furthermore, the compounds can be administered in combination with other drugs, either in a common pharmaceutical composition or as separate pharmaceutical compositions, where the separate pharmaceutical compositions can be provided in the form of a kit of parts. The compounds are preferably administered in conventional dosage forms prepared by combining the drugs with standard pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating, and compressing or dissolving the ingredients as appropriate for the desired preparation. It will be appreciated that the form and characteristics of the pharma-ceutically acceptable carrier or diluent will be determined by the amount of active ingredient to be combined, the route of administration, and other well-known variables.

[0160] The excipient must be acceptable in the sense of being compatible with the other ingredients of the formulation and, within the scope of sound medical judgment, suitable for use in contact with the patient's tissues without undue toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. Preferably, the excipient is not harmful to the recipient. The excipient employed may be, for example, a solid, gel, or liquid carrier. Exemplary solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, and the like. Exemplary liquid carriers are phosphate buffered saline solution, syrup, oils such as peanut oil and olive oil, water, emulsions, various types of wetting agents, sterile solutions, and the like. Similarly, the carrier or diluent may include a time-delay material well known in the art, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The suitable carriers include those described above and others well known in the art, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solution, dextrose solution and Hank's solution. In addition, the pharmaceutical composition or formulation can also contain other carriers, adjuvants, or non-toxic, non-therapeutic, non-immunogenic stabilizers, etc. When solutions for infusion or injection are used, they are preferably aqueous solutions or suspensions, which can be generated before use, for example, from lyophilized preparations containing the active substance as such or together with carriers, such as mannitol, lactose, glucose, albumin, etc. Ready-made solutions are sterilized and, if appropriate, mixed with excipients, for example, preservatives, stabilizers, emulsifiers, solubilizers, buffers and / or salts for adjusting osmotic pressure. Sterilization can be obtained by sterile filtration, using filters having small pore sizes, where appropriate, through which the composition can be lyophilized. Small amounts of antibiotics can also be added to ensure maintenance of sterility.

[0161] The therapeutically effective dose refers to the amount of compound to be used in the pharmaceutical composition of the present invention that prevents, ameliorates or treats symptoms associated with the disease or condition referred to in this specification.The therapeutic efficacy and toxicity of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, such as ED50 (the dose that is therapeutically effective in 50% of the population) and LD50 (the dose that is lethal to 50% of the population).The dose ratio between therapeutic effect and toxic effect is the therapeutic index, which can be expressed as the ratio LD50 / ED50.

[0162] The dosage regimen is determined by the attending physician and other clinical factors, preferably according to any one of the methods described above. As is well known in the medical art, the dosage for any one patient depends on many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concomitantly. Progress can be monitored by periodic assessment. Preferred doses are specified herein below. Progress can be monitored by periodic assessment. The pharmaceutical compositions and formulations referred to herein are administered at least once to treat or prevent the diseases or conditions listed herein. However, the pharmaceutical compositions can be administered more than once, for example, 1-10 times. Preferably, the pharmaceutical compositions can be administered at a frequency of once every 1-6 months, more preferably once every 2-4 months. Certain pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound referred to herein above in admixture or otherwise in association with a pharma- ceutically acceptable carrier or diluent. To prepare these specific pharmaceutical compositions, the active compound is usually mixed with a carrier or diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other suitable container or vehicle. The resulting formulation should be adapted to the mode of administration, i.e., in the form of a tablet, capsule, suppository, solution, suspension, etc. Dosage recommendations are provided in the prescriber or user instructions to anticipate dosage adjustments depending on the intended recipient.

[0163] The term "patient", as used herein, relates to a vertebrate, preferably a mammal, more preferably a human, monkey, cow, horse, cat or dog. Preferably, the mammal is a primate, more preferably a monkey, most preferably a human.

[0164] The dose of the compound according to formula (1) administered to the patient is preferably defined as the compound dose, i.e. the amount of compound administered to the patient. The preferred diagnostic compound dose is 1-10 nmol / total patient dose, and therefore preferably the diagnostic compound dose is 0.02-0.1 nmol / kg body weight. The preferred therapeutic compound dose is 10-100 nmol / total patient dose, and therefore preferably the therapeutic compound dose is 0.2-1 nmol / kg body weight.

[0165] As will be understood by the skilled artisan, the dosage of the complex as specified herein, i.e. the complex comprising, preferably consisting of, a radionuclide and a compound according to formula (1), is preferably indicated as a compound dosage as specified above, the preferred dosage being the same as specified above. More preferably, the dosage of the complex is indicated as an active dosage, i.e. the amount of radioactivity administered to the patient. Preferably, the active dosage is adjusted to avoid adverse effects as specified elsewhere herein. Preferably, the patient-specific dosage, preferably the patient-specific active dosage, is determined taking into account relevant factors as specified elsewhere herein, in particular taking into account the treatment progress and / or adverse effects observed for each patient. Thus, preferably, the active dosage is adjusted so that the organ-specific dose in the salivary gland is at most 30 Sv, more preferably less than 20 Sv, even more preferably less than 10 Sv, most preferably less than 5 Sv.

[0166] The effective amount can be administered to a patient at an active dose of about 2MBq to about 30MBq, preferably 4 to 30Mbq, more preferably 6 to 30Mbq, more preferably 8 to 30Mbq, more preferably 10 to 30Mbq, more preferably 15 to 30Mbq, and preferably 20 to 30Mbq once (single dose). Therefore, the preferred therapeutic dose in such a case is 2MBq to about 30MBq / patient, preferably 4 to 30Mbq / patient, more preferably 6 to 30Mbq / patient, more preferably 8 to 30Mbq / patient, more preferably 10 to 30Mbq / patient, more preferably 15 to 30Mbq / patient, and preferably 20 to 30Mbq / patient. Preferably, the active dosage ranges from about 10 to 30 MBq per administration, such as about 10MBq, 11MBq, 12MBq, 13MBq, 14MBq, 15MBq, 16MBq, 17MBq, 18MBq, 19MBq, 20MBq, 21MBq, 22MBq, 23MBq, 24MBq, 25MBq, 26MBq, 27MBq, 28MBq, 29MBq or 30MBq, or any range between any two of the above values. However, higher or lower doses may be expected depending on the type of radiation emitted by the radionuclide and / or the application, as specified herein below. The phrase "effective amount" or "therapeutically effective amount", as used herein, means an amount of a compound, material or composition including a compound of the invention, or other active ingredient, that is effective to produce some desired therapeutic effect in at least a subpopulation of cells in a patient, at a reasonable benefit / risk ratio applicable to any medical treatment. A therapeutically effective amount with respect to a compound of the invention means an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment or prevention of a disease. The term used in connection with a compound of the invention can include an amount that improves overall treatment, reduces or avoids the symptoms or causes of a disease, or enhances the therapeutic effectiveness of or synergy with another therapeutic agent.

[0167] According to a preferred embodiment, the radionuclide is a β-emitter as specified herein above, more preferably 177Lu and the use is diagnostic, in such cases the active dose of the complex is preferably at least 100 kBq / kg body weight, more preferably at least 500 kBq / kg body weight, most preferably at least 1 MBq / kg body weight. More preferably, the radionuclide is a β-emitter as specified herein above, more preferably 177 Lu and the use is in the treatment, preferably the treatment of prostate carcinoma as specified elsewhere herein, in which case the active dose of the complex is preferably at least 25 MBq / kg body weight, more preferably at least 50 MBq / kg body weight, most preferably at least 80 MBq / kg body weight. Thus, the preferred therapeutic dose in such cases is 2-10 GBq / patient, more preferably 4-8 GBq / patient, most preferably about 6 GBq / patient.

[0168] More preferably, the radionuclide is an α-emitter as specified herein above, more preferably 225 Ac and the use is the treatment, preferably the treatment of prostate carcinoma as specified elsewhere herein, in such cases the active dose of the complex is preferably in the range of 25 kBq / kg to about 500 kBq / kg of body weight of said patient, more preferably the active dose of the complex is at least 75 kBq / kg body weight, more preferably at least 100 kBq / kg body weight, even more preferably at least 150 kBq / kg body weight, most preferably at least 200 kBq / kg body weight. Thus, preferably in such cases the active dose of the complex is 75 to 500 kBq / kg body weight, more preferably 100 to 400 kBq / kg body weight, even more preferably 150 to 350 kBq / kg body weight, most preferably 200 to 300 kBq / kg body weight.

[0169] The present invention also relates to a compound as described above or below, a complex as described above or below, or a pharmaceutical composition as described herein above, for use in diagnosis, preferably for diagnosing a cell proliferative disease or disorder, in particular prostate cancer and / or metastasis thereof.Furthermore, the present invention also relates to a compound as described above or below, a complex as described above or below, or a pharmaceutical composition as described herein above or below, for use in medicine, preferably for treating or preventing a cell proliferative disease or disorder, in particular prostate cancer and / or metastasis thereof.

[0170] The term "diagnosing" as used herein refers to determining whether a subject suffers or does not suffer from a disease or disorder, preferably a cell proliferative disease or disorder. As will be understood by those skilled in the art, such a determination is preferably 100% correct, but may not usually be correct for 100% of the subjects examined. The term, however, preferably requires that a statistically significant proportion of subjects can be correctly determined and therefore diagnosed. Whether a portion is statistically significant can be determined by those skilled in the art without further ado using various well-known statistical evaluation tools, such as confidence interval determination, p-value determination, Student's t-test, Mann-Whitney test, etc. Details can be found in Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983. Preferred confidence intervals are at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95%. The p-value is preferably 0.2, 0.1 or 0.05. As will be understood by those skilled in the art, diagnosing may include further diagnostic determinations, such as visual and / or manual inspection, determining tumor biomarker concentrations in a subject's sample, x-ray examination, etc. The term includes individual diagnosis of a patient as well as continuous monitoring of a patient. Monitoring the presence or absence of a cell proliferative disease or symptoms associated therewith at various times, i.e. diagnosing, includes monitoring of a patient known to suffer from a cell proliferative disease as well as monitoring of a subject known to be at risk of developing a cell proliferative disease. Furthermore, monitoring can also be used to determine whether a patient is successfully treated or whether at least symptoms of a cell proliferative disease can be ameliorated over time by a particular treatment. Furthermore, the term also includes classifying a subject according to a conventional classification scheme, such as T1-T4 staging, known to those skilled in the art.

[0171] The terms "treating" and "treatment" refer to the amelioration of a disease or disorder or symptoms associated therewith to a significant extent. Said treating, as used herein, also includes the restoration of overall health with respect to a disease or disorder referred to herein. It should be understood that treating, as used herein, may not be effective in all subjects to be treated. However, the term should preferably require that a statistically significant proportion of subjects suffering from a disease or disorder referred to herein can be successfully treated. Whether a portion is statistically significant can be determined without further ado by those skilled in the art using various well-known statistical evaluation tools as specified herein above. The terms "preventing" and "prevention" refer to maintaining health in a subject for a certain period of time with respect to a disease or disorder referred to herein. It will be understood that said period of time may depend on the amount of drug compound administered and the individual factors of the subject as discussed elsewhere in this specification. It should be understood that prevention may not be effective in all subjects treated with a compound according to the present invention. However, the term preferably requires that a statistically significant proportion of subjects of a cohort or population is effectively prevented from suffering from the disease or disorder referred to herein or symptoms associated therewith. Preferably, the cohort or population of subjects in this context is expected to develop the disease or disorder referred to herein normally, i.e. without the preventive measures according to the invention. Whether a portion is statistically significant can be determined without further ado by those skilled in the art using various well-known statistical evaluation tools discussed herein above.

[0172] Preferably, the treatment and / or prevention comprises the administration of at least one compound according to formula (1) and / or at least one complex as specified elsewhere herein, more preferably in an active dose and / or compound dose as specified above.

[0173] The term "cell proliferative disorder" as used herein relates to a disease in animals, including humans, characterized by uncontrolled growth by a population of somatic cells ("cancer cells"). This uncontrolled growth may involve the invasion and destruction of cancer cells into surrounding tissues, and possibly their spread (metastasis) to other locations in the body. Preferably, recurrence is also included by the term cancer. Thus, preferably, the cancer is a solid cancer, a metastatic cancer, or a recurrence thereof. Preferably, the cell proliferative disorder is uncontrolled proliferation of cells, including cells expressing PSMA.

[0174] Therefore, preferably, the cell proliferative disease is a PSMA-expressing cancer. The term "PSMA-expressing cancer" refers to any cancer in which cancer cells express prostate-specific membrane antigen (PSMA). Preferably, the cancer (or cancer cells) that can be treated according to the present invention is selected from among prostate cancer, conventional renal cell carcinoma, transitional cell carcinoma of the bladder, lung cancer, testicular embryonic carcinoma, neuroendocrine carcinoma, colon cancer, brain tumor and breast cancer, more preferably selected from among PSMA-positive prostate cancer, PSMA-positive renal cell carcinoma, PSMA-positive transitional cell carcinoma of the bladder, PSMA-positive lung cancer, PSMA-positive testicular embryonic carcinoma, PSMA-positive neuroendocrine carcinoma, PSMA-positive colon cancer, PSMA-positive brain tumor and PSMA-positive breast cancer. Whether a cancer is PSMA-positive can be determined by a person skilled in the art by methods known in the art, for example in vitro, by immunostaining a cancer sample, or in vivo, for example by PSMA scintigraphy, preferably both as described in Kratochwil et al. (2017, J Nucl Med 58(10):1624. In a particularly preferred embodiment of the present invention, the PSMA-expressing cancer is prostate or breast cancer, more preferably prostate cancer, even more preferably advanced stage prostate cancer. Thus, preferably, the cell proliferative disorder is prostate cancer stage T2, more preferably stage T3, most preferably stage T4. Preferably, the cell proliferative disorder is metastatic prostate cancer, more preferably metastatic castration-resistant prostate cancer. Advantageously, it has been shown in the studies underlying the present invention that administration of the compounds and / or complexes of the present invention to a patient results in a reduced uptake of said compounds and / or complexes by the salivary and lacrimal glands, i.e. the salivary and lacrimal glands of the patient, for example when compared to the uptake of the commonly used PSMA-617 on the other hand. Due to the reduced uptake, adverse side effects on the salivary and / or lacrimal glands can be avoided and / or reduced. This is advantageous since adverse side effects on the salivary glands are considered as dose limiting (Kratochwil et al. (2017, J Nucl Med 58(10):1624).Based on the findings of the present invention, when compared with the compounds and complexes described in the art, a larger amount of compound and / or complex, and in particular a higher dose of radioactivity, can be administered to patients.Therefore, the therapeutic window is wider than with the compounds currently used.Moreover, advantageously, the compounds of the present invention provide improved diagnosis, because the co-labeling of non-related tissues and organs, particularly salivary gland, lacrimal gland and / or kidney, is reduced.

[0175] Thus, the compounds and / or complexes of the present invention allow for the treatment of PSMA-expressing cancers, particularly prostate cancer and its metastases, and / or the diagnosis of PSMA-expressing cancers, particularly prostate cancer and its metastases, where adverse side effects on the salivary glands and / or lacrimal glands of patients are avoided and / or reduced. Thus, said treatment and / or diagnosis has less or less severe adverse side effects on the salivary glands and / or lacrimal glands, or preferably does not involve any adverse side effects on the salivary glands and / or lacrimal glands. Preferably, the compounds of the present invention allow for the reduction and / or avoidance of adverse side effects on the salivary glands and / or lacrimal glands while maintaining essentially unchanged therapeutic efficacy, and thus, preferably, the excretion properties of the compounds of the present invention are essentially unchanged compared to PSMA-617.

[0176] Thus, the compounds and / or complexes of the invention allow for the treatment of PSMA-expressing cancers, particularly prostate cancer and metastases thereof, and / or the diagnosis of PSMA-expressing cancers, particularly prostate cancer and metastases thereof, wherein xerostomia symptoms are avoided.

[0177] Preferably, the compounds as described above or below, or the complexes as described above or below, or the pharmaceutical compositions as described above or below, are used for in vivo imaging and radiotherapy. Suitable pharmaceutical compositions may contain a radioactive imaging agent or a radiotherapeutic agent having a radionuclide either as an element, i.e., radioactive iodine, or as a radioactive metal chelate complex of the compound of formula (la) and / or (lb) in an amount sufficient for imaging, together with a pharma- ceutically acceptable radiological vehicle. The radiological vehicle should be suitable for injection or inhalation, such as human serum albumin; aqueous buffer solutions, such as tris(hydromethyl)-aminomethane (and its salts), phosphate buffers, citrate buffers, bicarbonate buffers, and the like; sterile water, saline; and balanced ionic solutions containing chloride and / or dicarbonate salts, or normal blood plasma cations, such as calcium, potassium, sodium, and magnesium.

[0178] The concentration of the imaging or therapeutic agent in the radiological vehicle should be sufficient to provide satisfactory imaging. Appropriate dosages are described herein above. The imaging or therapeutic agent should be administered so as to remain in the patient for about 1 hour to 10 days, although both longer and shorter time periods are acceptable. Thus, convenient ampoules containing 1 to 10 mL of aqueous solution may be prepared.

[0179] Imaging can be performed in a manner known to those skilled in the art, for example, by injecting a sufficient amount of the imaging composition to provide adequate imaging, followed by scanning with a suitable imaging or scanning machine, for example, a tomography or gamma camera. In certain embodiments, a method of imaging an area in a patient includes the steps of: (i) administering to the patient a diagnostically effective amount of a compound complexed with a radionuclide, (ii) exposing the area of ​​the patient to a scanning device, and (ii) obtaining an image of the area of ​​the patient. In certain embodiments, the area to be imaged is the head or thorax. In other embodiments, the compounds and complexes of formula l(a) and / or (lb) target PSMA protein.

[0180] Thus, in some embodiments, a method of imaging a tissue, e.g., spleen tissue, kidney tissue, or PSMA-expressing tumor tissue, is provided that includes contacting the tissue with a complex synthesized by contacting a radionuclide and a compound of Formula (la) and / or Formula (lb).

[0181] The amount of a formulation containing a compound of the invention, or a complex of said compound, or a salt, solvate, stereoisomer or tautomer thereof, administered to a patient will depend on several physiological factors, which are known by the physician, including the nature of the imaging to be performed, the tissue to be targeted for imaging or treatment, and the weight and medical history of the patient to be imaged or treated with the radiopharmaceutical.

[0182] Thus, in another aspect, the present invention provides a method of treating a patient suffering from a cell proliferative disease or disorder by administering to the patient a therapeutically effective amount of a complex as described above or below for treating the patient. In particular, the cell proliferative disease or disorder to be treated or imaged using the compounds, pharmaceutical compositions or radiopharmaceuticals according to this invention is cancer, e.g., prostate cancer and / or prostate cancer metastases, e.g., in the lung, liver, kidney, bone, brain, spinal cord, bladder, etc.

[0183] The compounds of the present invention can be synthesized, for example, in solution as well as on solid phase, for example, using standard peptide coupling procedures, for example, Fmoc solid phase coupling procedures. Preferably, the chelator is coupled to the remaining part of the molecule in the last coupling step, followed by a deprotection step and, in the case of solid phase chemistry, cleavage from the resin. However, other synthesis procedures are possible and known to those skilled in the art. A preferred synthesis of the compounds of the present invention is described in detail in the Examples section.

[0184] By way of example, particularly preferred compounds of the invention are shown in Table 1.

[0185] [Table 1] TIFF0007584426000030.tif213168

[0186] Preferably, the compound has the structure

[0187] [ka] TIFF0007584426000032.tif234164TIFF0007584426000033.tif94165.

[0188] More preferably, the compound has the structure

[0189] [ka] TIFF0007584426000035.tif138164, more preferably

[0190] [ka] TIFF0007584426000037.tif139165.

[0191] Particularly preferably, the compound has the structure

[0192] [ka] has.

[0193] As outlined above, the amino acids E and H preferably have the L configuration. More preferably, the compound therefore has the following structure:

[0194] [ka] and more preferably, the compound has a structure selected from the group consisting of:

[0195] [ka] TIFF0007584426000043.tif181165, and more preferably, the compound has the structure

[0196] [ka] The compound has a structure selected from the group consisting of:

[0197] To summarise the findings of the present invention, the following embodiments are preferred: 1. Equation (1)

[0198] [ka] (In the formula, R 1 is H or -CH3, preferably H; R 2 , R 3 and R 4are each independently selected from the group consisting of -CO2H, -SO2H, -SO3H, -OSO3H, -PO2H, -PO3H and -OPO3H2; Q 1 is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl, and heteroaryl; Q 2is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl and alkylheteroaryl; A is selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (=DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 1, 4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonane-1-yl)pentanedioic acid (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononanephosphinic acid (TRAP), 1,4,7-triazacyclononanephosphinic acid (TRAP), Rononane phosphinic acid (TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)phosphinic acid]-4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO), 3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (=PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[ X is a chelator residue derived from a chelator selected from the group consisting of 5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A), p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA); 1 , X 2 , Y 1 , Y 2 , Z1 and Z 2 are each independently a charged amino acid; q is an integer from 0 to 3; n, m, and p are each independently an integer from 0 to 9; n1, n2, m1, m2, p1, and p2 are each independently an integer from 0 to 3; n1+n2>0, m1+m2>0, and p1+p2>0; and n+m+p>0. or a pharma- ceutically acceptable salt or solvate thereof. 2. A:

[0199] [ka] The compound of embodiment 1, wherein the chelator moiety has a structure selected from the group consisting of: 3. The compound according to embodiment 1 or 2, wherein (n1+n2)n + (m1+m2)m + (p1+p2)p is at least 2. 4. The compound according to any one of embodiments 1 to 3, wherein (n1+n2)n + (m1+m2)m + (p1+p2)p is an integer from 2 to 20, preferably from 2 to 10, more preferably from 4 to 8, more preferably 6. 5. Q 1 preferably comprises a residue selected from the group consisting of naphthyl, phenyl, biphenyl, indolyl, benzothiazolyl, naphthylmethyl, phenylmethyl, biphenylmethyl, indolylmethyl and benzothiazolylmethyl, more preferably Q 1 but,

[0200] [ka] Preferably, Q is selected from the group consisting of 1 but

[0201] [ka] The compound of any one of embodiments 1 to 4, wherein 6. R 3 , R 2 and R4 is -CO2H, and R 1 The compound of any one of embodiments 1 to 5, wherein 7. Q 2 but,

[0202] [ka] and preferably

[0203] [ka] 7. The compound of any one of embodiments 1 to 6, wherein 8. A compound according to any one of embodiments 1 to 7, wherein n1, n2, m1, m2, p1, and p2 are, independently of each other, 0 or 1. 9. X 1 , X 2 , Y 1 , Y 2 , Z 1 and Z 2 are, independently of each other, positively or negatively charged amino acids at physiological pH. 10. The compound according to embodiment 9, wherein the positively charged amino acids are independently selected from the group consisting of arginine, lysine, histidine homoarginine, 3- and 4-substituted arginine analogues, N(delta)-methyl-arginine (delta MA), canavanine, substituted analogues of canavanine, α-amino-β-guanidinopropionic acid, γ-guanidinobutyric acid, citrulline, 3-guanidinopropionic acid, 4-{[amino(imino)methyl]amino}butanoic acid, 6-{[amino(imino)methyl]amino}hexanoic acid, 2-amino-3-guanidinopropionic acid, arginine hydroxamate, agmatine (CAS number: 2482-00-0), and NG-methyl-arginine, and preferably the basic amino acids are independently selected from the group consisting of lysine (K), histidine (H) and arginine (R). 11. The compound according to embodiment 9 or 10, wherein the negatively charged amino acids are independently selected from the group consisting of homoglutamic acid, sulfonic acid derivatives of Cys, cysteic acid, homocysteic acid, aspartic acid (D), glutamic acid (E), preferably the acidic amino acids are independently selected from aspartic acid and glutamic acid. 12. X 1 and X 2 at least one of X is a positively charged amino acid; 1 and X 2 12. The compound of any one of embodiments 1 to 11, wherein at least one of is a negatively charged amino acid. 13. X 1 and X 2 At least one of X is histidine (H), 1 and X 2 13. The compound of any one of embodiments 1 to 12, wherein at least one of is glutamic acid (E). 14. A compound according to any one of embodiments 1 to 13, wherein n1 is 0 or 1 and n2 is 0 or 1. 15. Building Blocks ((X 1 ) n1 (X 2 ) n2 ) n But structure (HE) n or (EH) n , preferably (EH) n The compound of any one of embodiments 1 to 14, having the following structure: 16. Y 1 and Y 2 is a positively charged amino acid, and Y 1 and Y 2 16. The compound of any one of embodiments 1 to 15, wherein at least one of is a negatively charged amino acid. 17. Y 1 and Y 2 is histidine (H), and Y 1 and Y 2 17. The compound of any one of embodiments 1 to 16, wherein at least one of is glutamic acid (E). 18. A compound according to any one of the preceding embodiments, wherein m1 is 0 or 1 and m2 is 0 or 1. 19. Building Blocks (Y 1 ) m1 (Y 2 ) m2 ) m But structure (HE) m or (EH) m , preferably (EH) m 19. The compound of any one of embodiments 1 to 18, having the following structure: 20. Z 1 and Z 2 at least one of Z is a positively charged amino acid; 1 and Z 2 20. The compound of any one of embodiments 1 to 19, wherein at least one of is a negatively charged amino acid. 21. Z 1 and Z 2 At least one of is histidine (H), and Z 1 and Z 2 21. The compound of any one of embodiments 1 to 20, wherein at least one of is glutamic acid (E). 22. A compound according to any one of the preceding embodiments, wherein p1 is 0 or 1 and p2 is 0 or 1. 23. Building Blocks (Z 1 ) p1 (Z 2 ) p2 ) p But structure (HE) p or (EH) p , preferably (EH) p 23. The compound of any one of embodiments 1 to 22, having the following structure: 24. A compound according to any one of embodiments 1 to 23, wherein n+m+p >1. 25. Building Blocks ((X 1 ) n1 (X 2 ) n2 ) n But structure (HE) n or (EH) nwherein n is 2-4, more preferably 3; m is 0; and p is 0. 26. Building Blocks (Y 1 ) m1 (Y 2 ) m2 ) m But structure (HE) m or (EH) m wherein m is 2-4, more preferably 3; n is 0; and p is 0. 27. Building Blocks (Z 1 ) p1 (Z 2 ) p2 ) p But structure (HE) p or (EH) p wherein p is 2-4, more preferably 3; n is 0; and m is 0. 28. Structure

[0204] [ka] and H and E preferably have the L configuration. 29. Structure

[0205] [ka] and H and E preferably have the L configuration. 30. Structure

[0206] [ka] and H and E preferably have the L configuration. 31. Structure

[0207] [ka] and H and E preferably have the L configuration. 32. (a) Radionuclides, and (b) A compound according to any one of embodiments 1 to 31, or a pharma- ceutically acceptable salt or solvate thereof. A complex comprising: 33. A radioactive nuclide is 89 Zr, 44 Sc, 111 ln, 90 Y, 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Cu, 67 Cu, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 161 Tb, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac, 230 U, 223 Ra, 165 Er, 52 Fe, 59 Fe, and Pb radionuclides (e.g., 203 Pb and 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 Pb, 198 Pb, 197 33. The complex of embodiment 32, wherein the complex is selected from the group consisting of: 34. A pharmaceutical composition comprising a compound according to any one of embodiments 1 to 31 or a complex according to embodiment 32 or 33. 35. A compound according to any one of embodiments 1 to 31, or a complex according to embodiment 32 or 33, or a pharmaceutical composition according to claim 34, for use in medicine, preferably for treating and / or preventing PSMA-expressing cancer, in particular prostate cancer and / or metastasis thereof. 36. The compound of embodiment 35, in which adverse side effects on the salivary and / or lacrimal glands are reduced and / or avoided. 37. A compound according to any one of embodiments 1 to 31, or a complex according to embodiment 32 or 33, or a pharmaceutical composition according to embodiment 34, for use in diagnostic medicine. 38. The compound according to embodiment 37, for use in the diagnosis of cancer, preferably of PSMA-expressing cancer, in particular of prostate cancer and / or metastasis thereof. 39. The radionuclide is a β-emitter, more preferably 177 Lu, and the use is diagnostic, more preferably the active dosage of the complex is at least 100 kBq / kg body weight, more preferably at least 500 kBq / kg body weight, most preferably at least 1 MBq / kg body weight. 40. The radionuclide is an α-emitter, more preferably 225 The compound according to any one of embodiments 34 to 38, wherein Ac is a teratoma tumor suppressor, the use being in the treatment, preferably in the treatment of a PSMA-expressing cancer, preferably prostate cancer, and the active dose of the complex is preferably at least 75 kBq / kg body weight, more preferably at least 100 kBq / kg body weight.

[0208] All references cited throughout this specification are incorporated herein by reference in their entirety as well as with respect to the disclosure content that is specifically stated.

[0209] The following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention in any way.

[0210] [Example] All commercially available chemicals were of analytical grade and were used without further purification. 68 Ga]GaCl4 - teeth 68 Ge / 68 Obtained from a Ga generator (Eckert & Ziegler). 177 [Lu]LuCl3 was obtained from ITG. Compounds were analyzed using reversed-phase high-performance liquid chromatography (RP-HPLC; Chromolith RP-18e, 100 × 4.6 mm; Merck, Darmstadt, Germany). Analytical HPLC runs were performed using a linear gradient from 5% (A) (0.1% TFA in water) to 50% B (0.1% TFA in CH3CN) within 24 min at 1 mL / min.

[0211] Analytical HPLC runs were performed using an Agilent 1200 Series system (Agilent Technologies, Santa Clara, California, USA). UV absorbance was measured at 220 and 280 nm, respectively. For mass spectrometry, an LC-MS SQ300 (Perkin Elmer, Waltham, Massachusetts, USA) was used.

[0212] The precursors PSMA-617 (2-[3-(1-carboxy-5-{3-naphthalen-2-yl-2-[(4-{[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetylamino]-methyl}-cyclohexanecarbonyl)-amino]-propionylamino}-pentyl)-ureido]-pentanedioic acid) and PSMA-10 ([Glu-urea-Lys(Ahx)]2-HBED-CC) were purchased from ABX, Radeberg, Germany.

[0213] I. Synthesis I.1 Synthesis of compounds PS1 to PS10 Unless otherwise indicated, compounds were synthesized as follows.

[0214] The synthesis of the pharmacophore Glu-urea-Lys was carried out according to Schafer M et al. (2012), EJNMMI Res. 2(1):23. Briefly, the synthesis started with the formation of the isocyanate of the glutamyl moiety using triphosgene. Resin-immobilized (2-chloro-trityl resin, Merck, Darmstadt) ε-allyloxycarbonyl-protected lysine was added and reacted for 16 h under gentle agitation. The resin was filtered off and the allyloxy-protecting group was removed by reacting twice with Pd(PPh3)4 (0.3 equiv.) and morpholine (15 equiv.) under ambient conditions (1 h, room temperature). The resin was split and the linker was introduced by the standard Fmoc solid-phase protocol. According to the amino acid sequences of PS1–PS10, Fmoc-protected amino acids (4 equiv. each) were coupled in DMF with HATU (4 equiv.) and DIPEA (10 equiv.). After coupling of the last amino acid of the sequence, tris(tBu)DOTA (tris(tBu)-ester of 1,4,7,10 tetraazacyclododecane-1,4,7,10-tetraacetic acid) (4 equiv. each) was coupled with HATU (4 equiv.) and DIPEA (10 equiv.) in DMF. The product was cleaved from the resin with TFA / TIPS / HO (95 / 2.5 / 2.5, v / v / v) for 3 h at room temperature.

[0215] All products were purified using RP-HPLC and identified by mass spectrometry.

[0216] Purification was performed using a semi-preparative column (SemiPrep, Chromolith RP-18e, 100 × 10 mm; Merck, Darmstadt, Germany). Solvent A consisted of 0.1% TFA in water and solvent B was 0.1% TFA in CH3CN.

[0217] The following compounds were synthesized:

[0218] [Table 2]

[0219] I.268 Ga labeling The precursor peptide [2 nmol, 40 μL in HEPES buffer (1 M, pH 7)] was added to 40 μL of [ 68 Ga]GaCl4 - (approximately 30 MBq) was added. The reaction mixture was incubated at 95° C. for 15 min. The radiochemical yield (RCY) was determined by HPLC.

[0220] I.3 177 Lu labeling The precursor peptide [1 nmol, 50 μL in HEPES buffer (0.1 M, pH 7.2)] was added to 10 μL of [ 177 To the reaction mixture was added [Lu]LuCl3 (approximately 30 MBq). The reaction mixture was incubated at 95° C. for 15 min. The radiochemical yield (RCY) was determined by HPLC.

[0221] I.4 [Example 1] Synthesis of DOTA-(EH)3-CHx-2NaI-Lys-Urea-Glu and DOTA-CHx-2NaI-(EH)3-Lys-Urea-Glu The synthesis of the pharmacophore Glu-urea-Lys was carried out according to Schafer M et al. (2012), EJNMMI Res. 2(1):23. Briefly, the synthesis started with the formation of the isocyanate of the glutamyl moiety using triphosgene. Resin-immobilized (2-chloro-trityl resin, Merck, Darmstadt) ε-allyloxycarbonyl-protected lysine was added and reacted for 16 h under gentle agitation. The resin was filtered off and the allyloxy protecting group was removed by reacting twice with Pd(PPh3)4 (0.3 equiv.) and morpholine (15 equiv.) under ambient conditions (1 h, room temperature). The resin was split and the linker was introduced by the standard Fmoc solid-phase protocol.

[0222] Synthesis of DOTA-(EH)3-CHx-2NaI-Lys-Urea-Glu In the first step, Fmoc-2-NaI-OH and N-Fmoc-tranexamic acid (4 eq. each) were coupled with HATU (4 eq.) and DIPEA (10 eq.) in DMF. To introduce (HE)3, the coupling of Fmoc-His(Trt)-OH and Fmoc-Glu(otBu)-OH (4 eq.) was carried out with HATU (4 eq.) and DIPEA (10 eq.). To form (HE)3, the coupling of Fmoc-His(Trt)-OH and Fmoc-Glu(otBu)-OH was repeated, respectively. Subsequently, tris(tBu)DOTA (tris(tBu)-ester of 1,4,7,10 tetraazacyclododecane-1,4,7,10-tetraacetic acid) (4 eq. each) was coupled with HATU (4 eq.) and DIPEA (10 eq.) in DMF. The product was cleaved from the resin using TFA / TIPS / H2O (95 / 2.5 / 2.5, v / v / v) for 3 h at room temperature.

[0223] Synthesis of DOTA-CHx-2NaI-(EH)3-Lys-urea-Glu In the first step, the coupling of Fmoc-His(Trt)-OH and Fmoc-Glu(otBu)-OH (4 eq.) was carried out in DMF using HATU (4 eq.) and DIPEA (10 eq.). The coupling of Fmoc-His(Trt)-OH and Fmoc-Glu(otBu)-OH, respectively, was repeated to form (HE)3. Then, Fmoc-2-NaI-OH and N-Fmoc-tranexamic acid (4 eq. each) were coupled in DMF using HATU (4 eq.) and DIPEA (10 eq.). Subsequently, tris(tBu)DOTA (tris(tBu)-ester of 1,4,7,10 tetraazacyclododecane-1,4,7,10-tetraacetic acid) (4 eq. each) was coupled in DMF using HATU (4 eq.) and DIPEA (10 eq.). The product was cleaved from the resin using TFA / TIPS / H2O (95 / 2.5 / 2.5, v / v / v) for 3 h at room temperature.

[0224] All products were purified using RP-HPLC and identified by mass spectrometry.

[0225] Purification was performed using a NUCLEOSIL column (VP250 / 21, 5 μm particles, 120-5 C18; Macherey-Nagel, Duren, Germany). Solvent A consisted of 0.1% TFA in water and solvent B was 0.1% TFA in CH3CN.

[0226] 177 Lu labeling The precursor peptide [1 nmol, 50 μL in HEPES buffer (0.1 M, pH 7.2)] was added to 10 μL of [ 177 To the reaction mixture was added [Lu]LuCl3 (approximately 30 MBq). The reaction mixture was incubated at 95° C. for 30 min. The radiochemical yield (RCY) was determined by HPLC.

[0227] II. Cellular assays II.1 Cell culture PSMA + LNCaP cells (ATCC CRL-1740) were cultured in RPMI medium. Cells were grown at 37°C in humidified air with 5% CO2 and harvested using trypsin-ethylenediaminetetraacetic acid.

[0228] II.2 Cell Binding and Internalization Competitive cell binding assays and internalization experiments were performed according to Eder M et al. (2012), Bioconjug Chem 23(4):688.

[0229] Briefly, cells (10 per well) were 5 )of 68The cells were incubated in the presence of 12 different concentrations of analyte (0–5000 nM, 100 μL / well) with a 0.8 nM solution of Ga-labeled radioligand [Glu-Urea-Lys(Ahx)]2-HBED-CC (PSMA-10, precursor ordered from ABX, Radeberg, Germany). After incubation, the mixture was removed and the wells were washed three times with PBS using a multiscreen vacuum manifold (Millipore, Billerica, MA). Cell-bound radioactivity was measured using a gamma counter (Packard Cobra II, GMI, Minnesota, USA). The 50% inhibitory concentration (IC50) values ​​were calculated by fitting the data using a nonlinear regression algorithm (GraphPad software).

[0230] For internalization experiments, 10 cells per well 5 The cells were seeded onto poly-L-lysine coated 24-well cell culture plates 24 h prior to incubation. After washing, the cells were treated with 30 nM 68 Ga or 177 Lu radiolabeled compounds were incubated for 45 min at 37° C. and 4° C., respectively. Cell uptake was terminated by washing three times with 1 mL ice-cold PBS. To remove surface-bound radioactivity, cells were incubated twice for 5 min with 0.5 mL glycine-HCl in PBS (50 mM, pH=2.8). Cells were washed with 1 mL ice-cold PBS and lysed using 0.3 N NaOH (0.5 mL). Surface-bound and internalized fractions were measured in a gamma counter. Cell uptake was measured using 10 5 The percent of initial radioactivity bound to cells [%ID / 10 5 The total number of cells was calculated as [cells per 100].

[0231] statistical aspects All experiments were performed in at least triplicate and repeated at least three times. Quantitative data were expressed as mean ± SD. Where applicable, means were compared using Student's t-test. A P value <0.05 was considered statistically significant.

[0232] III. μPET Imaging For μPET imaging, mice were anesthetized (2% isoflurane) and placed in a small animal PET scanner (PET Focus, Siemens) and 500 pmol of 68 Ga-labeled peptide was injected. Dynamic scans of 60 min and static scans at 60 and 120 min pi were performed. Images were reconstructed and converted to standard uptake values ​​(SUVs) shown in maximum intensity projection (MIP) images and time activity curves. Quantification was performed using the ROI (region of interest) technique and expressed as SUV mean.

[0233] IV. Results To investigate the effect of the linker on the binding properties, the internalization efficiency of the compounds was determined. The results are summarized in Table 1. Both synthetic compounds show significantly higher specific cell surface binding and specific internalization compared to the standard PSMA-617.

[0234] [Table 3]

[0235] [Table 4]

[0236] [Table 5]

[0237] [Table 6]

[0238] Pharmacokinetic studies in PSMA+ tumor-bearing BALB / c nude mice: 0.5 nmol in LNCaP tumor-bearing athymic nude mice (right trunk) 68Time activity curves for the kidney following injection of Ga-labeled compounds up to 60 min pi are shown in Figure 1. (SUV = standard uptake value)

[0239] Furthermore, 0.5 nmol of IFN-γ in LNCaP tumor-bearing athymic nude mice (right trunk) 68 The time activity curves (SUV = standard uptake value) for tumor and muscle following injection of Ga-labeled compound X at up to 60 min pi are shown in the following figures:

[0240] [Table 7]

[0241] [Table 8] (Additional Note) (Appendix 1) Formula (1) [ka] (In the formula, R 1 is H or -CH3, preferably H; R 2 , R 3 and R 4 are independently selected from the group consisting of -CO2H, -SO2H, -SO3H, -OSO3H, -PO2H, -PO3H and -OPO3H2; Q 1 is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl, and heteroaryl; Q 2 is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, and alkylheteroaryl; A is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (=DOTA), N,N''-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA), 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid, (NODAGA), 2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAGA), 1,4,7-triazacyclononanephosphinic acid (TRAP), 1,4,7-triazacyclononane-1-[methyl(2-carboxyethyl)benzyl]ethylenediamine-N,N''-diacetic acid, 4,7-bis[methyl(2-hydroxymethyl)phosphinic acid] (NOPO), 3,6,9,15-tetraazabicyclo[9.3.1.]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (=PCTA), N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide (DFO), diethylenetriaminepentaacetic acid (DTPA), trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-DTPA), 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (oxo-Do3A) p-isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), and 1-(2)-methyl-4-isocyanatobenzyl-DTPA (MX-DTPA); X 1 , X 2 , Y 1 , Y 2 , Z 1 and Z 2 are, independently of each other, charged amino acids, q is an integer from 0 to 3, n, m, and p are each independently an integer from 0 to 9; n1, n2, m1, m2, p1, and p2 are each independently an integer of 0 to 3; n1+n2 > 0, m1+m2 > 0, and p1+p2 > 0, n+m+p > 0) or a pharma- ceutically acceptable salt or solvate thereof. (Appendix 2) A, [ka] The compound of claim 1, wherein the chelator moiety has a structure selected from the group consisting of: (Appendix 3) The compound of claim 1 or 2, wherein (n1+n2)n + (m1+m2)m + (p1+p2)p is at least 2. (Appendix 4) The compound according to any one of Appendices 1 to 3, wherein (n1+n2)n + (m1+m2)m + (p1+p2)p is an integer of 2 to 20, preferably 2 to 10, more preferably 4 to 8, and more preferably 6. (Appendix 5) Q 1 preferably comprises a residue selected from the group consisting of naphthyl, phenyl, biphenyl, indolyl, benzothiazolyl, naphthylmethyl, phenylmethyl, biphenylmethyl, indolylmethyl and benzothiazolylmethyl, more preferably Q 1 but, [ka] Preferably, Q is selected from the group consisting of 1 but [ka] 5. The compound according to any one of claims 1 to 4, (Appendix 6) R 3 , R 2 and R 4is -CO2H, and R 1 The compound of any one of claims 1 to 5, wherein (Appendix 7) Q 2 but, [ka] and preferably [ka] 7. The compound according to any one of claims 1 to 6, (Appendix 8) X 1 , X 2 , Y 1 , Y 2 , Z 1 and Z 2 are, independently of one another, positively or negatively charged amino acids at physiological pH, and the positively charged amino acids are, independently of one another, arginine, lysine, histidine, homoarginine, 3- and 4-substituted arginine analogues, N(delta)-methyl-arginine (delta MA), canavanine, substituted analogues of canavanine, α-amino-β-guanidinopropionic acid, γ-guanidinobutyric acid, citrulline, 3-guanidinopropionic acid, 4-{[amino(imino)methyl]amino}-butyric acid, 5-[[amino(imino)methyl]amino]-butyric acid, 6-[[amino(imino)methyl]amino]-butyric acid, 7-[[amino(imino)methyl]amino]-butyric acid, 8-[[amino(imino)methyl]amino]-butyric acid, 9-[[amino(imino)methyl]amino]-butyric acid, 10-[[amino(imino)methyl]amino]-butyric acid, 11-[[amino(imino)methyl]amino]-butyric acid, 12-[[amino(imino)methyl]amino]-butyric acid, 13-[[amino(imino)methyl]amino]-butyric acid, 14-[[amino(imino)methyl]amino]-butyric acid, 15-[[amino(imino)methyl]amino]-butyric acid, 16-[[amino(imino)methyl]amino]-butyric acid, 17-[[amino(imino)methyl]amino]-butyric acid, 18-[[amino(imino)methyl]amino]-butyric acid, 19-[[amino(imino)methyl]amino]-butyric acid, 20-[[amino(imino)methyl]amino]-butyric acid, 21-[[amino(imino)methyl]amino]-buty 8. The compound according to any one of claims 1 to 7, wherein the basic amino acids are selected from the group consisting of 6-{[amino(imino)methyl]amino}hexanoic acid, 6-{[amino(imino)methyl]amino}hexanoic acid, 2-amino-3-guanidinopropionic acid, arginine hydroxamate, agmatine (CAS number: 2482-00-0) and NG-methyl-arginine, preferably the basic amino acids are selected independently from each other from the group consisting of lysine (K), histidine (H) and arginine (R). (Appendix 9) X 1 , X 2 , Y 1 , Y 2 , Z 1 and Z 2are, independently of one another, positively or negatively charged amino acids at physiological pH, and the negatively charged amino acids are, independently of one another, selected from the group consisting of homoglutamic acid, sulfonic acid derivatives of Cys, cysteic acid, homocysteic acid, aspartic acid (D), glutamic acid (E), preferably the acidic amino acids are, independently of one another, selected from aspartic acid and glutamic acid. (Appendix 10) (a) Radionuclides, and (b) A compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt or solvate thereof. A complex comprising: (Appendix 11) The radioactive nuclide is 889 Zr, 44 Sc, 111 ln, 90 Y, 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Cu, 67 Cu, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 161 Tb, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac, 230 U, 223 Ra, 165 Er, 52 Fe, 59 Fe, and Pb radionuclides (e.g., 203 Pb and 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 Pb, 198 Pb, 197 11. The complex of claim 10, wherein the compound is selected from the group consisting of: (Appendix 12) A pharmaceutical composition comprising a compound according to any one of claims 1 to 9 or a complex according to claim 10 or 11. (Appendix 13) A compound according to any one of appendices 1 to 9, or a complex according to appendices 10 or 11, or a pharmaceutical composition according to appendix 12, for use in medicine, preferably for treating or preventing a PSMA-expressing cancer, in particular prostate cancer and / or metastasis thereof. (Appendix 14) A compound according to any one of appendices 1 to 9, or a complex according to appendices 10 or 11, or a pharmaceutical composition according to appendix 12, for use in a diagnostic agent. (Appendix 15) A compound according to claim 14 for use in the diagnosis of cancer, preferably of PSMA-expressing cancer, in particular of prostate cancer and / or metastasis thereof.

Claims

1. Formula (1) 【Chemistry 1】 (In the formula, R 1 is H or -CH 3 and R 2 , R 3 and R 4 are independent of each other, -CO 2 H, -SO 2 H, -SO 3 H, -OSO 3 H, -PO 2 H, -PO 3 H and -OPO 3 H 2 is selected from the group consisting of Q 1 teeth, 【Chemistry 2】 and Q 2 teeth, 【Chemistry 3】 and X 1 , X 2 , Y 1 , Y 2 , Z 1 and Z 2 are each independently a charged amino acid selected from the group consisting of histidine (H) and glutamic acid (E), and at least one of X 1 and X 2 is glutamic acid; q is 1, n, m and p are each independently an integer from 0 to 9; n1, n2, m1, m2, p1, and p2 are each independently an integer from 0 to 3; (n1+n2)n is 2 to 10, (m1+m2)m + (p1+p2)p = 0, A is, 【Chemistry 4】 is a chelating agent residue having a structure selected from the group consisting of or a pharma- ceutically acceptable salt or solvate thereof.

2. R 3 , R 2 and R 4 Ga-CO 2 H and R 1 or a pharma- ceutically acceptable salt or solvate thereof, according to claim 1, wherein

3. (a) Radionuclides, and (b) A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or solvate thereof. A complex comprising:

4. The radioactive nuclide is 889 Zr, 44 Sc, 111 ln, 90 Y, 66 Ga, 67 Ga, 68 Ga, 177 Lu, 99m Tc, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Cu, 67 Cu, 149 Tb, 152 Tb, 155 Tb, 153 Sm, 161 Tb, 153 Gd, 155 Gd, 157 Gd, 213 Bi, 225 Ac, 230 U, 223 Ra, 165 Er, 52 Fe, 59 Fe, and Pb radionuclides (e.g., 203 Pb and 212 Pb, 211 Pb, 213 Pb, 214 Pb, 209 Pb, 198 Pb, 197 4. The complex of claim 3, wherein the moiety is selected from the group consisting of:

5. 5. A pharmaceutical composition comprising a compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or solvate thereof, or a complex according to claim 3 or 4.

6. 10. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or solvate thereof, or a complex according to claim 3 or 4, or a pharmaceutical composition according to claim 5, for use in medicine.

7. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or solvate thereof, or a complex according to claim 3 or 4, or a pharmaceutical composition according to claim 5, for treating or preventing a PSMA-expressing cancer.

8. 10. A compound according to claim 1 or 2 or a pharma- ceutically acceptable salt or solvate thereof, or a complex according to claim 3 or 4, or a pharmaceutical composition according to claim 5, for treating or preventing prostate cancer and / or metastasis thereof.

9. 10. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or solvate thereof, or a complex according to claim 3 or 4, or a pharmaceutical composition according to claim 5, for use in a diagnostic agent.

10. 10. A compound according to claim 1 or 2, or a pharma- ceutically acceptable salt or solvate thereof, or a complex according to claim 3 or 4, or a pharmaceutical composition according to claim 5, for use in the diagnosis of PSMA-expressing cancer.

Citation Information

Patent Citations

  • Radiolabeled prostate-specific membrane antigen inhibitors

    JP2014524419A

  • Novel tumor antigen-binding agent and its use

    JP2022509220A

  • PSMA-targeting imaging agents

    US20150209453A1